Bharat Biotech

Covaxin safe, well-tolerated in 2-18 years age-group, Bharat Biotech cites Lancet study

A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal.

published on : 17th June 2022

Predicted pandemic in December 2019 before COVID spread across the world: Bharat Biotech founder

"I said a pandemic will come because signals are coming. As I said, exactly three months later COVID came into the picture," said the Bharat Biotech founder Krishna Ella.

published on : 17th June 2022

‘Covaxin booster improves efficacy against two variants’: Bharat Biotech

A booster dose of Covaxin enhances vaccine effectiveness against Delta and Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech said. 

published on : 16th June 2022

Covaxin booster improves efficacy against Delta, Omicron variants: ICMR study

The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge were observed, said the study.

published on : 15th June 2022

Germany to recognise Covaxin for travel purpose from June 1, says envoy

In November last year, the World Health Organisation recommended Emergency Use Listing (EUL) status for Covaxin.

published on : 26th May 2022

FDA lifts hold on Covaxin's clinical trials in US

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab.

published on : 24th May 2022

Bharat Biotech seeks DCGI nod for phase 2/3 Covaxin booster trial among two to 18-year-old

Presently, precaution dose of Covaxin and Covishield is administered to all those aged above 18 who have completed nine months after the second dose.

published on : 4th May 2022

Bharat Biotech's Covaxin gets emergency approval for 6-12 age group

The company said it conducted clinical trials in the paediatric population between June 2021 to September 2021 and results have shown robust safety, reactogenicity, and immunogenicity.

published on : 26th April 2022

Ocugen to commercialise Covaxin in Mexico

City-based pharma major Bharat Biotech’s US partner Ocugen, Inc. has got the permission to commercialise  Covid vaccine Covaxin in Mexico.

published on : 19th April 2022

Bharat Biotech expands Covaxin pact with Ocugen to enter North America market

The Hyderabad-based pharma major has also sought EUA for use of Covaxin for children in the 2-18 years age group in Mexico.

published on : 18th April 2022

Covaxin's phase 2/3 clinical trials put on hold in the US

The WHO had earlier suspended supply through UN agencies of Coavaxin after inspectors identified good manufacturing practice deficiencies in the company's pharma plant.

published on : 14th April 2022

Covishield & Covaxin prices cut, hospitals to pay Rs 225 per dose

The precautionary dose has to be of the same vaccine used for the first two doses.

published on : 10th April 2022

Serum Institute, Bharat Biotech cut COVID vaccine prices for private hospitals to Rs 225

The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.

published on : 9th April 2022

No impact of WHO action on Covaxin, have not supplied to any UN agency: Bharat Biotech

So far, sources said, the firm has supplied vaccines to the Indian government and nine countries under the Centre's Vaccine Maitri programme, and has made direct commercial supply under EUA.

published on : 4th April 2022

WHO suspends UN supply of Covaxin; Bharat Biotech says no impact on efficacy

The WHO also asked countries that have received India's indigenous Covid-19 vaccine to take appropriate actions, however, it did not specify what the appropriate actions would be.

published on : 3rd April 2022
1 2 3 4 5 >